Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
enGene Holdings (ENGN)
NASDAQ:ENGN
enGene Holdings (ENGN) Stock Price & Analysis
19 Followers
ENGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.69 - $47.17
Previous Close$8.99
Volume73.64K
Average Volume (3M)116.60K
Market Cap
$397.05M
Enterprise Value$156.93M
Total Cash (Recent Filing)$264.81M
Total Debt (Recent Filing)$24.68M
Price to Earnings (P/E)―
Beta-1.83
Next Earnings
Jun 14, 2024EPS Estimate
-$0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.36
Shares Outstanding44,166,159
10 Day Avg. Volume188,561
30 Day Avg. Volume116,598
Standard Deviation0.45
R-Squared0.09
Alpha0.00055
Financial Highlights & Ratios
Price to Book (P/B)5.48
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-14.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-11.08
Forecast
1Y Price Target
$23.00Price Target Upside155.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
enGene Holdings News
PremiumCompany Announcements
enGene Holdings Unveils Updated Corporate Strategy Presentation
PremiumCompany Announcements
enGene Holdings Shareholders Back Directors and Equity Plan
Bulls Say, Bears Say
Bulls Say
EfficacyEG-70 demonstrates a better than expected 6 month complete response rate greater than 60% and any time complete response rate of 75%, which appears stronger than what was observed in prior Phase 1 data and favorable to competing candidates.
Market PotentialThe company's lead product candidate in BCG-unresponsive NMIBC has the potential to become the preferred agent in this large market given its potential efficacy and ease-of-use profile.
SafetySafety updates look favorable with limited to no Grade 3 treatment-related adverse events and no Grade 4+ treatment-related adverse events.
Bears Say
Regulatory TimelineThe expected BLA filing timeline is now mid-2026 due in part to lighter enrollment in the last few months.
Safety ConcernsSafety data from Anktiva + BCG treatment showed that 16% of patients experienced serious adverse events, including one fatal cardiac arrest.
Trial DelayThe brief trial delay is a disappointment.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ENGN FAQ
What was enGene Holdings’s price range in the past 12 months?
enGene Holdings lowest stock price was $6.69 and its highest was $47.17 in the past 12 months.
What is enGene Holdings’s market cap?
Currently, no data Available
When is enGene Holdings’s upcoming earnings report date?
enGene Holdings’s upcoming earnings report date is Jun 14, 2024 which is 38 days ago.
How were enGene Holdings’s earnings last quarter?
enGene Holdings released its earnings results on Mar 11, 2024. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.415 by -$0.045.
Is enGene Holdings overvalued?
According to Wall Street analysts enGene Holdings’s price is currently Undervalued.
Does enGene Holdings pay dividends?
enGene Holdings does not currently pay dividends.
What is enGene Holdings’s EPS estimate?
enGene Holdings’s EPS estimate is -$0.26.
How many shares outstanding does enGene Holdings have?
enGene Holdings has 44,166,160 shares outstanding.
What happened to enGene Holdings’s price movement after its last earnings report?
enGene Holdings reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.415. Following the earnings report the stock price went down -10%.
Which hedge fund is a major shareholder of enGene Holdings?
Among the largest hedge funds holding enGene Holdings’s share is Omega Fund Management, LLC. It holds enGene Holdings’s shares valued at 18M.
---
enGene Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.00 (155.84% Upside)
$23.00 (155.84% Upside)
Blogger Sentiment
Bullish
ENGN Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $788.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.52%
12-Months-Change
Fundamentals
Return on Equity
-68.39%
Trailing 12-Months
Asset Growth
100.98%
Trailing 12-Months
Company Description
enGene Holdings
Forbion European Acquisition Corp is a blank check company.
---
ENGN Stock 12 Month Forecast
Average Price Target
$23.00
▲(155.84% Upside)
Technical Analysis
Best Analysts Covering ENGN
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-34.86%
reiterated a buy rating last month
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -34.86% per trade.
---